經動脈化療栓塞術市場規模、佔有率及成長分析（依手術類型、產品類型、適應症、最終用戶和地區）－2025 年至 2032 年產業預測

預計 2023 年經動脈化療栓塞術 (TACE) 市場規模將達到 102 億美元，並從 2024 年的 106.6 億美元成長到 2032 年的 151.6 億美元，預測期內（2025-2032 年）的複合年成長率為 4.5%。

全球經動脈化療栓塞術 (TACE) 市場正在應對因肝炎感染、飲酒和非酒精性脂肪肝等因素導致的肝癌盛行率上升，導致消費者偏好因治療肝臟腫瘤的微創方法而改變。醫療技術的創新使得 TACE 手術更加複雜、更準確、成本更低，從而增加了需求。人們對肝癌症狀以及早期診斷重要性的認知不斷提高，尤其是對於中期肝癌患者，這鼓勵他們儘早尋求治療。然而，市場動態因地區而異，並受到醫療保健基礎設施、風險因素發生率、法律規範等的影響。由於肝癌發生率高，亞太地區，尤其是中國，出現了顯著的成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

動脈化療栓塞術市場規模（依手術類型和複合年成長率） (2025-2032)

• 市場概覽
• 常規TACE
• DEB-TACE

動脈化療栓塞市場規模（依產品類型和複合年成長率） (2025-2032)

• 市場概覽
• 化療
• 放射治療劑
• 藥物釋放型顆粒

動脈化療栓塞市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概覽
• 不可切除的肝細胞癌
• 早期肝細胞癌

動脈化療栓塞市場規模（依最終使用者和複合年成長率）(2025-2032)

• 市場概覽
• 醫院和診所
• 癌症研究中心

動脈化療栓塞術市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Meril Life Sciences（India）
• MicroPort（China）
• Terumo Corporation（Japan）
• Ethicon（Johnson & Johnson）（United States）
• Neusoft Medical Systems Co., Ltd.（China）
• Merit Medical Systems, Inc.（United States）
• Guerbet Group（France）
• AngioDynamics, Inc.（United States）
• Boston Scientific（United States）
• Medtronic（Ireland）
• Beckton Dickinson（United States）
• Cook Group（United States）
• HealthTronics（United States）
• IceCure Medical（Israel）
• Profound Medical（Canada）
• Siemens Healthineers（Germany）
• GE Healthcare（United States）
• Philips Healthcare（Netherlands）
• Sirtex Medical（Australia）
• BTG plc（United Kingdom）

結論和建議

Transarterial Chemoembolization Market size was valued at USD 10.2 billion in 2023 and is poised to grow from USD 10.66 billion in 2024 to USD 15.16 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global transarterial chemoembolization (TACE) market is experiencing a shift in consumer preferences due to its minimally invasive approach to treating hepatoma, in response to the rising prevalence of liver cancer driven by factors such as hepatitis infections, alcohol use, and non-alcoholic fatty liver disease. Innovations in medical technology have led to more sophisticated TACE procedures, enhancing accuracy and reducing costs, thereby boosting demand. Increased awareness regarding liver cancer symptoms and the importance of early diagnosis is prompting patients to seek treatment earlier, particularly for intermediate-grade cases. However, market dynamics vary by region, influenced by healthcare infrastructure, risk factor incidence, and regulatory frameworks, with significant growth observed in the Asia-Pacific region due to higher liver cancer rates, notably in China.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transarterial Chemoembolization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transarterial Chemoembolization Market Segments Analysis

Global Transarterial Chemoembolization Market is segmented by Procedure Type, Product Type, Indication, End-User and region. Based on Procedure Type, the market is segmented into Conventional TACE and DEB-TACE. Based on Product Type, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents and Drug-eluting Particles. Based on Indication, the market is segmented into Unresectable HCC and Early-Stage HCC. Based on End-User, the market is segmented into Hospitals and Clinics and Cancer Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is being propelled by the rising global prevalence of liver cancer, which necessitates effective treatment options. In addition, advancements in medical technology are enhancing the precision and effectiveness of these therapeutic procedures, influencing both healthcare providers and patients to opt for TACE. The appeal of minimally invasive techniques plays a significant role in the growth of this market, as they minimize discomfort and pain compared to conventional treatment approaches. As the demand for innovative and less intrusive cancer treatment continues to grow, TACE is emerging as a favored choice among patients and oncologists alike.

Restraints in the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market faces significant challenges stemming from the diverse nature of liver cancer patients and their varied responses to treatment. This complexity necessitates a tailored approach to TACE, hindering its widespread adoption. Additionally, stringent regulations surrounding the approval and reimbursement of medical procedures further constrain market growth. Variations in reimbursement policies and lengthy regulatory approval processes can impede the integration of TACE into standard healthcare practices, ultimately limiting its accessibility and use among patients. Consequently, these factors collectively act as significant restraints on the TACE market, affecting its overall development and implementation.

Market Trends of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is witnessing a significant trend towards personalized medicine, which emphasizes tailored treatment approaches for liver cancer patients. Healthcare providers are increasingly exploring customized TACE strategies based on individual patient characteristics, overall health status, and specific tumor types. This shift aligns with the broader movement toward precision medicine, aiming to optimize patient outcomes through bespoke therapies. Additionally, technological innovations are revolutionizing the TACE landscape, with ongoing research focused on enhancing the precision and efficacy of treatment. Advances in embolic agents, drug-eluting bead technologies, and imaging tools are enabling more targeted interventions, ensuring that the therapeutic impact on cancerous tissues is maximized while minimizing harm to surrounding healthy organs. This dual trend of personalization and technology integration is poised to drive growth in the TACE market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Transarterial Chemoembolization Market Size by Procedure Type & CAGR (2025-2032)

• Market Overview
• Conventional TACE
• DEB-TACE

Global Transarterial Chemoembolization Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Chemotherapeutic Agents
• Radiotherapeutic Agents
• Drug-eluting Particles

Global Transarterial Chemoembolization Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Unresectable HCC
• Early-Stage HCC

Global Transarterial Chemoembolization Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Cancer Research Centers

Global Transarterial Chemoembolization Market Size & CAGR (2025-2032)

• North America (Procedure Type, Product Type, Indication, End-User)
  • US
  • Canada
• Europe (Procedure Type, Product Type, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Procedure Type, Product Type, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Procedure Type, Product Type, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Procedure Type, Product Type, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Meril Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon (Johnson & Johnson) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neusoft Medical Systems Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckton Dickinson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Group (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HealthTronics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IceCure Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Profound Medical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirtex Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BTG plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations